Tag: Indivior

In July 2024, pharmaceutical manufacturer Indivior announced its decision to stop all sales and marketing activities for its schizophrenia drug, Perseris® (risperidone). For patients currently on this long-acting injectable medication, understanding the implications of whether **Is Perseris still available?** is crucial for ensuring a seamless transition and continuity of care.

Effective July 9, 2024, pharmaceutical company Indivior announced it would discontinue all sales and marketing activities for its schizophrenia drug, Perseris. This strategic move was not prompted by any safety or efficacy issues with the product but was a business decision based on financial viability, which answers the question: **Why is Perseris being discontinued**?. The market withdrawal was driven by increased payor management impacts and a competitive market landscape influenced by the Inflation Reduction Act.

Suboxone is a key medication in treating opioid use disorder, with its active ingredient buprenorphine being a gold standard in treatment. The question 'Why are they discontinuing Suboxone?' stems from a crucial market shift, not an abandonment of the therapy.

In a July 2024 announcement, pharmaceutical company Indivior revealed it would cease promoting and selling its schizophrenia medication, Perseris. This decision, driven by market pressures and financial viability concerns rather than any safety or efficacy issues, left many asking: **why was Perseris discontinued**?